Astec Lifesciences Ltd

₹ 695 -0.81%

30 Apr - close price

About

The Company is into manufacturing of agrochemical active ingredients (technical), bulk and formulations, intermediate products and it sells its products in India as well as exports them to approximately 24 countries.
Astec also has undertaken a number of custom synthesis projects, for its clients in Europe, Japan and the US. It is present only in business to business sale (B2B).^[1] ^[2] ^[3]

Key Points

Product Portfolio
The company offers a range of products and intermediates, including fungicides, insecticides, herbicides, and various chemical compounds, serving global customers and including triazole fungicides, heterocyclic herbicides, sulfonylurea herbicides, synthetic pyrethroids, fluorinated compounds, halides, intermediates, ketones, ethers, alcohols, and many others. ^[1]

Website BSE NSE

Market Cap ₹ 1,548 Cr.
Current Price ₹ 695
High / Low ₹ 991 / 512
Stock P/E
Book Value ₹ 175
Dividend Yield 0.00 %
ROCE -5.47 %
ROE -25.3 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Cons

Stock is trading at 3.97 times its book value
Company has low interest coverage ratio.
The company has delivered a poor sales growth of -4.18% over past five years.
Company has a low return on equity of -26.1% over last 3 years.
Company might be capitalizing the interest cost
Company has high debtors of 202 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Commodities Chemicals Fertilizers & Agrochemicals Pesticides & Agrochemicals

Part of BSE Commodities BSE 1000

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	126.97	142.85	110.79	50.79	153.75	69.37	98.55	93.86	119.53	91.08	73.72	124.72	158.62
	121.57	139.71	114.21	69.12	141.04	115.62	118.28	99.60	114.01	102.07	80.39	120.72	149.46
Operating Profit	5.40	3.14	-3.42	-18.33	12.71	-46.25	-19.73	-5.74	5.52	-10.99	-6.67	4.00	9.16
OPM %	4.25%	2.20%	-3.09%	-36.09%	8.27%	-66.67%	-20.02%	-6.12%	4.62%	-12.07%	-9.05%	3.21%	5.77%
	2.57	1.70	0.96	0.90	2.03	0.91	1.98	1.89	0.78	0.49	1.09	-1.30	2.61
Interest	6.41	6.47	6.00	6.10	6.68	7.05	9.34	9.92	10.40	11.05	8.41	7.18	7.93
Depreciation	7.77	9.40	9.17	8.72	9.02	9.28	11.49	11.42	11.59	11.51	10.46	11.24	11.79
Profit before tax	-6.21	-11.03	-17.63	-32.25	-0.96	-61.67	-38.58	-25.19	-15.69	-33.06	-24.45	-15.72	-7.95
Tax %	-19.48%	-25.66%	-23.77%	-24.50%	3.12%	-35.56%	-0.00%	60.42%	2.61%	-0.00%	-0.00%	-0.00%	-2.01%
	-5.00	-8.21	-13.45	-24.35	-0.99	-39.74	-38.57	-40.40	-16.10	-33.06	-24.45	-15.72	-7.78
EPS in Rs	-2.23	-3.67	-6.00	-10.87	-0.44	-17.74	-17.22	-18.04	-7.19	-14.76	-10.97	-7.06	-3.49
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	252	221	298	368	431	522	555	677	628	458	381	448
	200	190	236	299	354	437	443	522	551	464	447	453
Operating Profit	52	31	63	69	76	85	112	154	77	-6	-66	-5
OPM %	21%	14%	21%	19%	18%	16%	20%	23%	12%	-1%	-17%	-1%
	-15	-0	-8	12	11	12	8	10	13	5	6	3
Interest	12	12	12	11	12	13	5	9	21	25	37	35
Depreciation	12	10	14	15	19	23	26	34	34	36	44	45
Profit before tax	12	8	29	56	56	61	89	121	35	-62	-141	-81
Tax %	-18%	95%	33%	37%	36%	23%	27%	26%	27%	-24%	-4%	-0%
	15	0	19	35	36	47	65	90	26	-47	-135	-81
EPS in Rs	6.65	0.16	8.56	15.68	16.00	21.19	28.88	40.10	11.39	-20.98	-60.18	-36.36
Dividend Payout %	16%	-0%	15%	8%	8%	6%	5%	3%	12%	-0%	-0%	-0%

Compounded Sales Growth
10 Years:	7%
5 Years:	-4%
3 Years:	-11%
TTM:	18%

Compounded Profit Growth
10 Years:	%
5 Years:	%
3 Years:	%
TTM:	42%

Stock Price CAGR
10 Years:	12%
5 Years:	-8%
3 Years:	-20%
1 Year:	5%

Return on Equity
10 Years:	2%
5 Years:	-8%
3 Years:	-26%
Last Year:	-25%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	19	19	20	20	20	20	20	20	20	20	20	22
Reserves	117	99	118	150	183	227	289	376	399	349	214	368
	93	127	127	125	176	99	188	280	341	494	555	449
	128	84	69	119	83	227	182	221	219	111	92	102
Total Liabilities	358	329	334	413	461	572	678	897	979	974	880	941
	127	94	103	115	167	194	213	340	318	386	499	478
CWIP	12	20	8	42	19	24	116	23	127	165	21	0
Investments	1	0	0	0	0	0	0	0	0	0	0	0
	217	214	223	256	275	354	349	534	533	423	360	462
Total Assets	358	329	334	413	461	572	678	897	979	974	880	941

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	3	3	19	65	15	169	-8	23	74	10	-8	-81
	-14	-16	-18	-49	-52	-74	-73	-104	-112	-135	-15	-4
	11	15	-1	-18	37	-95	81	80	38	125	24	94
Net Cash Flow	-0	2	1	-2	-0	0	0	0	-0	-0	0	9
Free Cash Flow	-13	-23	-1	15	-37	123	-111	-80	-42	-125	-24	-85
CFO/OP	11%	27%	41%	116%	42%	219%	13%	34%	103%	-208%	20%	1,774%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	143	132	136	122	103	112	123	148	90	135	141	202
Inventory Days	143	186	133	122	121	131	113	176	268	224	196	169
Days Payable	181	179	117	156	83	219	137	180	161	102	100	107
Cash Conversion Cycle	105	140	152	88	141	24	99	145	197	256	237	263
Working Capital Days	17	-29	0	-8	-2	8	4	12	-17	-1	-26	-56
ROCE %	20%	10%	20%	22%	20%	20%	22%	22%	8%	-4%	-13%	-5%

Insights

In beta

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

CMO Revenue Contribution
%

		xx	xx	xx	xx	xx
			xx	xx	xxx
		x	x	x
xx	xx	xx
				xxx	xxx	xxx
		xx.xx	xx.xx	xx.xx
					xx.xx	xx.xx
			xx	xx
				x,xxx		x,xxx
				xx,xxx		xx,xxx
				xx
x.xx	x.xx	x.xx	x.xx	xx.xx	xx.xx	x.xx

Please log in to see hidden values.

Herbicide Plant Utilization
%

New CDMO Products Commercialized Per Year
Number

Product Concentration (Top 3 Products Revenue Share)
%

R&D Scientists (Headcount)
Number

Sales Volume Growth (Year-on-Year)
%

Export Share of Total Revenue
%

Imported Raw Material Dependency
%

Parent (GAVL) Agri-input Distributor Network
Number

Parent (GAVL) Oil Palm Plantation Area
Hectares

Parent (GAVL) Domestic Palm Oil Production Market Share
%

R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

6 Recently

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	66.76%	66.75%	66.75%	66.75%	66.75%	66.74%	66.74%	70.87%	70.87%	72.42%	71.97%	71.97%
	1.95%	1.33%	1.28%	1.25%	1.03%	0.53%	1.20%	0.25%	0.02%	0.00%	0.04%	0.03%
	10.15%	10.16%	9.74%	7.88%	3.37%	4.50%	5.40%	4.34%	4.26%	4.01%	3.17%	3.33%
	21.13%	21.74%	22.22%	24.12%	28.85%	28.20%	26.64%	24.53%	24.84%	23.57%	24.82%	24.67%
No. of Shareholders	18,703	18,722	19,244	19,848	19,955	19,727	19,057	18,689	18,549	18,276	22,293	21,041

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	65.54%	67.31%	67.62%	71.33%	65.23%	65.29%	66.76%	66.75%	70.87%	71.97%
	1.87%	0.77%	0.89%	0.84%	0.25%	0.32%	2.29%	1.25%	0.25%	0.03%
	0.27%	2.17%	2.10%	0.51%	10.67%	12.56%	10.58%	7.88%	4.34%	3.33%
	0.00%	0.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	32.32%	29.74%	29.39%	27.32%	23.85%	21.83%	20.37%	24.12%	24.53%	24.67%
No. of Shareholders	11,907	13,197	12,771	10,701	19,872	16,951	17,809	19,848	18,689	21,041

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

DRHP

Credit ratings

Concalls

Nov 2022
Transcript
PPT
Nov 2022
Transcript
PPT
May 2022
Transcript
PPT
Nov 2021
Transcript
PPT
Aug 2021
Transcript
PPT
Feb 2021
Transcript
PPT